MX2019001471A - Anticuerpos anti-siglec-7 para el tratamiento del cancer. - Google Patents
Anticuerpos anti-siglec-7 para el tratamiento del cancer.Info
- Publication number
- MX2019001471A MX2019001471A MX2019001471A MX2019001471A MX2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A
- Authority
- MX
- Mexico
- Prior art keywords
- siglec
- antibodies
- cancer
- treatment
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371680P | 2016-08-05 | 2016-08-05 | |
| PCT/US2017/045641 WO2018027203A1 (en) | 2016-08-05 | 2017-08-04 | Anti-siglec-7 antibodies for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001471A true MX2019001471A (es) | 2019-10-30 |
Family
ID=61073084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001471A MX2019001471A (es) | 2016-08-05 | 2017-08-04 | Anticuerpos anti-siglec-7 para el tratamiento del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11773162B2 (enExample) |
| EP (1) | EP3494142A4 (enExample) |
| JP (1) | JP7137563B2 (enExample) |
| KR (1) | KR20190035863A (enExample) |
| CN (1) | CN109790223A (enExample) |
| AU (1) | AU2017307616A1 (enExample) |
| BR (1) | BR112019002331A2 (enExample) |
| CA (1) | CA3032437A1 (enExample) |
| EA (1) | EA201990296A1 (enExample) |
| IL (1) | IL264674B2 (enExample) |
| MX (1) | MX2019001471A (enExample) |
| SG (1) | SG11201901020RA (enExample) |
| WO (1) | WO2018027203A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| IL264674B2 (en) | 2016-08-05 | 2023-09-01 | Allakos Inc | Antibodies to siglec7 for cancer treatment |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| WO2019011852A1 (en) * | 2017-07-10 | 2019-01-17 | Innate Pharma | POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2019140273A1 (en) | 2018-01-11 | 2019-07-18 | Allakos, Inc. | Anti-siglec-7 antibodies having reduced effector function |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20230210989A1 (en) * | 2020-06-03 | 2023-07-06 | Kar Muthumani | Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy |
| CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| JP2025027841A (ja) * | 2023-08-17 | 2025-02-28 | 国立大学法人 東京大学 | ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| WO2007120815A2 (en) * | 2006-04-12 | 2007-10-25 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| AU2008272330A1 (en) * | 2007-07-04 | 2009-01-08 | Forerunner Pharma Research Co., Ltd. | Anti-Muc17 antibody |
| CN104520324A (zh) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| ES3066738T3 (en) * | 2012-12-21 | 2026-05-14 | Aveo Pharmaceuticals Inc | Anti-gdf15 antibodies |
| EP2999717B1 (en) * | 2013-05-21 | 2018-08-08 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Treatment of mast cell related pathologies |
| ES2861313T3 (es) | 2014-08-07 | 2021-10-06 | Daiichi Sankyo Co Ltd | Anticuerpo anti Orai1 |
| JP2017532025A (ja) * | 2014-09-10 | 2017-11-02 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 交差反応性ｓｉｇｌｅｃ抗体 |
| CN115960235A (zh) * | 2015-08-28 | 2023-04-14 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| AU2017207807A1 (en) * | 2016-01-12 | 2018-07-12 | Palleon Pharmaceuticals Inc. | Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer |
| CN108699158B (zh) | 2016-03-08 | 2022-06-03 | 依奈特制药公司 | Siglec中和抗体 |
| IL264674B2 (en) | 2016-08-05 | 2023-09-01 | Allakos Inc | Antibodies to siglec7 for cancer treatment |
-
2017
- 2017-08-04 IL IL264674A patent/IL264674B2/en unknown
- 2017-08-04 WO PCT/US2017/045641 patent/WO2018027203A1/en not_active Ceased
- 2017-08-04 SG SG11201901020RA patent/SG11201901020RA/en unknown
- 2017-08-04 EP EP17837808.9A patent/EP3494142A4/en not_active Withdrawn
- 2017-08-04 JP JP2019527783A patent/JP7137563B2/ja not_active Expired - Fee Related
- 2017-08-04 CA CA3032437A patent/CA3032437A1/en active Pending
- 2017-08-04 CN CN201780060307.2A patent/CN109790223A/zh active Pending
- 2017-08-04 KR KR1020197006520A patent/KR20190035863A/ko not_active Ceased
- 2017-08-04 AU AU2017307616A patent/AU2017307616A1/en not_active Abandoned
- 2017-08-04 BR BR112019002331A patent/BR112019002331A2/pt not_active Application Discontinuation
- 2017-08-04 EA EA201990296A patent/EA201990296A1/ru unknown
- 2017-08-04 MX MX2019001471A patent/MX2019001471A/es unknown
- 2017-08-04 US US16/323,442 patent/US11773162B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017307616A1 (en) | 2019-02-28 |
| EP3494142A1 (en) | 2019-06-12 |
| EA201990296A1 (ru) | 2019-08-30 |
| CN109790223A (zh) | 2019-05-21 |
| WO2018027203A1 (en) | 2018-02-08 |
| JP2019526622A (ja) | 2019-09-19 |
| IL264674B1 (en) | 2023-05-01 |
| IL264674B2 (en) | 2023-09-01 |
| CA3032437A1 (en) | 2018-02-08 |
| EP3494142A4 (en) | 2020-04-01 |
| JP7137563B2 (ja) | 2022-09-14 |
| IL264674A (enExample) | 2019-03-31 |
| BR112019002331A2 (pt) | 2019-06-18 |
| US20190194323A1 (en) | 2019-06-27 |
| SG11201901020RA (en) | 2019-03-28 |
| KR20190035863A (ko) | 2019-04-03 |
| US11773162B2 (en) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| MX2024000300A (es) | Anticuerpos antitau y metodos de uso. | |
| PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
| EP3800248A3 (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| TW201613963A (en) | Anti-JAGGED1 antibodies and methods of use | |
| MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| EA201691896A1 (ru) | Соединения и способы их применения |